KMYY(SH:600518) 券商中国·2025-05-07 07:56Core Viewpoint - The article discusses the ongoing legal proceedings involving Kangmei Pharmaceutical and its lawsuit against Guangdong Zhengzhong Zhujiang Accounting Firm, highlighting the complexities and implications of the case in the context of China's capital market [1][2]. Summary by Sections Legal Proceedings - Kangmei Pharmaceutical has initiated a lawsuit against Guangdong Zhengzhong Zhujiang Accounting Firm for a compensation claim of 340.89 million yuan, following a previous court ruling that mandated the company to compensate 52,037 investors for losses totaling 2.45892854 billion yuan [4][5]. - The Guangzhou Intermediate People's Court has decided to take over the case due to its complexity and significance, with the trial scheduled for July 2025 [2][6]. Background of the Case - The lawsuit stems from a 2020 civil judgment where Kangmei was ordered to compensate investors due to false statements made by the company, with several individuals, including former executives, held jointly liable [8]. - The accounting firm has been implicated in failing to conduct due diligence during the audits of Kangmei's financial statements for the years 2016, 2017, and 2018, leading to administrative penalties imposed by the China Securities Regulatory Commission (CSRC) [10][11]. Financial Implications - The total compensation amount claimed by Kangmei includes not only the principal amount but also interest, litigation fees, and attorney fees, amounting to 340.89 million yuan [4]. - The CSRC has previously fined the accounting firm 42.75 million yuan and ordered the return of 14.25 million yuan in business income due to their negligence in auditing [11].